Publications de Patricia MARINO
Primary tabs
The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017.
European Journal of Cancer
2021
;
145
:
11 - 18.
Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort.
Journal of Clinical Oncology
2021
;
39
(6SUPPL)
:
220-220.
Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.
Value in Health
2020
;
23
(7)
:
pp. 898-906.
Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study.
Journal of Global Oncology
2019
;
5
(5)
:
1-9.
The role and use of Patient Reported Outcomes in the management of cancer patients.
Bulletin du Cancer
2018
;
105
(6)
:
603-609.
Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.
European Journal of Human Genetics
2018
;
26
(3)
:
pp. 314-323.
Sex Differences in the Return-to-Work Process of Cancer Survivors 2 Years After Diagnosis: Results From a Large French Population-Based Sample.
Journal of Clinical Oncology
2013
;
31
(10)
:
1277-1284.
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
Breast Cancer Research and Treatment
2010
;
129
(2)
:
401-409.
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.
Annals of Oncology
2010
;
21
(7)
:
1448-1454.
Impact of uncertainty on cost-effectiveness analysis of medical strategies: The case of high-dose chemotherapy for breast cancer patients.
International Journal of Technology Assessment in Health Care
2005
;
21
:
342-350.